Similarly, in the Th17-dominant setting of psoriasis, PRP regulates DC-T cell interactions by reducing peripheral blood Th17 cells, suppressing their secretion of IL-17, IL-22, and TNF-α, and enhancing the suppressive capacity of FOXP3+ Treg cells over effector T cells (14, 34). Here, IL17A is linked to psoriasis.